Gastrointestinal Cancer News

A randomized phase 3 trial designed to assess the addition of ibrutinib to chemotherapy for patients with metastatic pancreatic cancer failed to meet its primary endpoint of prolonged PFS.

The FDA approved trastuzumab-dttb, a biosimilar to trastuzumab, for three cancer indications.

Adjuvant durvalumab administered after trimodality therapy appeared safe for patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma, according to study results presented at Gastrointestinal Cancers Symposium.

Researchers discovered a substantial proportion of patients with newly diagnosed cancer and concurrent hepatitis C or hepatitis B were unaware of their viral infection and many had no identifiable risk factors, according to a recently published study.

Use of corticosteroids, certain dermatologic or mucosal conditions, and antibiotics all appeared to increase risk for chemotherapy-induced febrile neutropenia among a cohort of patients undergoing cancer treatment with myelosuppressive chemotherapy, according to study findings published in Journal of the National Comprehensive Cancer Network.

Using endoscopic full-thickness resection can help stratify patients with early colorectal cancer and allows patients with low-risk lesions to avoid surgery, according to research published in Gastrointestinal Endoscopy.

Pembrolizumab significantly improved OS compared with chemotherapy as second-line treatment for patients with advanced or metastatic esophageal or esophagogastric junction carcinoma whose tumors expressed PD-L1, according to results of the randomized phase 3 KEYNOTE-181 trial scheduled for presentation at this year’s Gastrointestinal Cancers Symposium.

Exelixis has announced it has received FDA approval for Cabometyx to treat patients with hepatocellular carcinoma who previously underwent treatment with Nexavar, according to a press release.

A phase 2 study designed to compare varlitinib with placebo as first-line treatment for certain patients with gastric cancer failed to meet its primary endpoint of significant reduction in tumor size after 12 weeks of treatment.

The Henry Ford Cancer Institute has announced that it has enrolled the first patient in a new trial to test the effectiveness of precise, higher dose MRI-guided radiation therapy to treat pancreatic cancer.